Biopharmaceutical ingredients

This segment spans recombinant ingredients and new technologies for the biopharmaceutical industry.

In 2007, focus was on integrating the activities we purchased in 2006, and completing a cGMP production expansion of the plant in Lund, Sweden. We entered into several partnership agreements regarding the development of biopharmaceutical ingredients for future pharmaceutical production. These agreements target sales some years into the future and follow Novozymes’ long-term strategy for this segment. Sales totaled DKK 224 million in 2007, a 67% increase. This increase can be attributed to the effect of acquired activities.

In 2008, sales are expected to be approximately 15% lower than in 2007. This is due to an expected decline in contract volumes and because sales in 2007 to clinical trials are not expected in 2008. Expectations for long-term growth
remain unchanged.

• Expected sales growth for 2008: -15%
• Expected long-term annual sales growth: 10-15%